Share this with FacebookShare this with TwitterShare this with LinkedInEmail this pagePrint this page
Saint Luke s Mid America Heart Institute Seeks Cardiovascular Outcomes Research Fellowship Applicants August 3, 2021
KANSAS CITY, Mo. - Saint Luke s Mid America Heart Institute one of the leading outcomes research centers in the nation is seeking highly motivated, talented individuals for its two-year postdoctoral training program in cardiovascular outcomes research. This National Heart, Lung, and Blood Institute funded T32 training program has openings for two fellowship positions beginning July 1, 2022. The T32 program is run by the University of Missouri-Kansas City (UMKC), and is hosted by Saint Luke s Mid America Heart Institute (SLMAHI) in close collaboration with the University of Kansas.
With Apple s backing, can an app help heart attack patients recover? statnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from statnews.com Daily Mail and Mail on Sunday newspapers.
EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Share Article
Saint Luke s Mid America Heart Institute shared trial findings at American College of Cardiology’s 2021 Scientific Session
The benefits observed were amongst the largest we have ever seen from a medication to improve the symptoms, function and quality of life of patients with heart failure. KANSAS CITY, Mo. (PRWEB) May 20, 2021 The EXPLORER-HCM (Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) Randomized Clinical Trial has shown significant improvement in the symptoms, function, and quality of life in patients with obstructive hypertrophic cardiomyopathy (oHCM) with taking mavecamten. This comes following no major advances for treating oHCM in more than 30 years, where the primary goals of treat
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients
Phase III DARE-19 trial shows SGLT2 inhibitor is well-tolerated in acutely ill patients
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.
May 18, 2021 Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 (SARS-CoV-2) who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology (ACC) 2021 Scientific Session.